Supplementary Figures 1-7 and Supplementary Methods from PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα

Supplementary Figure S1. Epithelial-mesenchymal transition and PHD3 silencing | Supplementary Figure S2. PHD3 silencing promotes EMT through upregulation of TGFα. | Supplementary Figure S3. EGFR signaling and TGFα mediate the effects of PHD3 silencing on EMT. | Supplementary Figure S4. EMT induced by PHD3 depletion is HIF dependent. | Supplementary Figure S5. PHD3 silencing confers resistance to erlotinib in EGFR mutant lung cancer cells. | Supplementary Figure S6. TGFα activates EGFR signaling in the presence of erlotinib. | Supplementary Figure S7. Resistance to erlotinib is associated with decreased PHD3 expression. | Supplementary Materials and Methods